Literature DB >> 21278085

The sigma-1 receptor enhances brain plasticity and functional recovery after experimental stroke.

Karsten Ruscher1, Mehrdad Shamloo, Mattias Rickhag, Istvan Ladunga, Liza Soriano, Lennart Gisselsson, Håkan Toresson, Lily Ruslim-Litrus, Donna Oksenberg, Roman Urfer, Barbro B Johansson, Karoly Nikolich, Tadeusz Wieloch.   

Abstract

Stroke leads to brain damage with subsequent slow and incomplete recovery of lost brain functions. Enriched housing of stroke-injured rats provides multi-modal sensorimotor stimulation, which improves recovery, although the specific mechanisms involved have not been identified. In rats housed in an enriched environment for two weeks after permanent middle cerebral artery occlusion, we found increased sigma-1 receptor expression in peri-infarct areas. Treatment of rats subjected to permanent or transient middle cerebral artery occlusion with 1-(3,4-dimethoxyphenethyl)-4-(3-phenylpropyl)piperazine dihydrochloride, an agonist of the sigma-1 receptor, starting two days after injury, enhanced the recovery of lost sensorimotor function without decreasing infarct size. The sigma-1 receptor was found in the galactocerebroside enriched membrane microdomains of reactive astrocytes and in neurons. Sigma-1 receptor activation increased the levels of the synaptic protein neurabin and neurexin in membrane rafts in the peri-infarct area, while sigma-1 receptor silencing prevented sigma-1 receptor-mediated neurite outgrowth in primary cortical neuronal cultures. In astrocytic cultures, oxygen and glucose deprivation induced sigma-1 receptor expression and actin dependent membrane raft formation, the latter blocked by sigma-1 receptor small interfering RNA silencing and pharmacological inhibition. We conclude that sigma-1 receptor activation stimulates recovery after stroke by enhancing cellular transport of biomolecules required for brain repair, thereby stimulating brain plasticity. Pharmacological targeting of the sigma-1 receptor provides new opportunities for stroke treatment beyond the therapeutic window of neuroprotection.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21278085     DOI: 10.1093/brain/awq367

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  67 in total

1.  Lymphocyte cell kinase activation mediates neuroprotection during ischemic preconditioning.

Authors:  Ok-Nam Bae; Krishnamurthy Rajanikant; Jiangyong Min; Jeremy Smith; Seung-Hoon Baek; Kelsey Serfozo; Siamak Hejabian; Ki Yong Lee; Mounzer Kassab; Arshad Majid
Journal:  J Neurosci       Date:  2012-05-23       Impact factor: 6.167

2.  σ1 receptors activate astrocytes via p38 MAPK phosphorylation leading to the development of mechanical allodynia in a mouse model of neuropathic pain.

Authors:  J Y Moon; D H Roh; S Y Yoon; S R Choi; S G Kwon; H S Choi; S Y Kang; H J Han; A J Beitz; S B Oh; J H Lee
Journal:  Br J Pharmacol       Date:  2014-11-24       Impact factor: 8.739

Review 3.  The Sigma-1 Receptor as a Pluripotent Modulator in Living Systems.

Authors:  Tsung-Ping Su; Tzu-Chieh Su; Yoki Nakamura; Shang-Yi Tsai
Journal:  Trends Pharmacol Sci       Date:  2016-02-09       Impact factor: 14.819

4.  Neuroprotective effects of high affinity Σ1 receptor selective compounds.

Authors:  Robert R Luedtke; Evelyn Perez; Shao-Hua Yang; Ran Liu; Suwanna Vangveravong; Zhude Tu; Robert H Mach; James W Simpkins
Journal:  Brain Res       Date:  2011-12-31       Impact factor: 3.252

5.  Albumin induces excitatory synaptogenesis through astrocytic TGF-β/ALK5 signaling in a model of acquired epilepsy following blood-brain barrier dysfunction.

Authors:  Itai Weissberg; Lydia Wood; Lyn Kamintsky; Oscar Vazquez; Dan Z Milikovsky; Allyson Alexander; Hannah Oppenheim; Carolyn Ardizzone; Albert Becker; Federica Frigerio; Annamaria Vezzani; Marion S Buckwalter; John R Huguenard; Alon Friedman; Daniela Kaufer
Journal:  Neurobiol Dis       Date:  2015-03-30       Impact factor: 5.996

6.  Delayed administration of a small molecule tropomyosin-related kinase B ligand promotes recovery after hypoxic-ischemic stroke.

Authors:  Jullet Han; Julia Pollak; Tao Yang; Mohammad R Siddiqui; Kristian P Doyle; Kereshmeh Taravosh-Lahn; Egle Cekanaviciute; Alex Han; Jeremy Z Goodman; Britta Jones; Deqiang Jing; Stephen M Massa; Frank M Longo; Marion S Buckwalter
Journal:  Stroke       Date:  2012-04-24       Impact factor: 7.914

7.  Resistance of optogenetically evoked motor function to global ischemia and reperfusion in mouse in vivo.

Authors:  Yicheng Xie; Shangbin Chen; Eitan Anenberg; Timothy H Murphy
Journal:  J Cereb Blood Flow Metab       Date:  2013-06-05       Impact factor: 6.200

Review 8.  Sigma-1 receptor chaperones in neurodegenerative and psychiatric disorders.

Authors:  Shang-Yi A Tsai; Michael J Pokrass; Neal R Klauer; Nicole E De Credico; Tsung-Ping Su
Journal:  Expert Opin Ther Targets       Date:  2014-10-21       Impact factor: 6.902

9.  The sigma-1 receptor mediates the beneficial effects of pridopidine in a mouse model of Huntington disease.

Authors:  Daniel Ryskamp; Jun Wu; Michal Geva; Rebecca Kusko; Iris Grossman; Michael Hayden; Ilya Bezprozvanny
Journal:  Neurobiol Dis       Date:  2016-11-03       Impact factor: 5.996

Review 10.  A possibly sigma-1 receptor mediated role of dimethyltryptamine in tissue protection, regeneration, and immunity.

Authors:  Ede Frecska; Attila Szabo; Michael J Winkelman; Luis E Luna; Dennis J McKenna
Journal:  J Neural Transm (Vienna)       Date:  2013-04-26       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.